What the paediatrician needs to know when pandemic influenza arrives in clinical practice.

作者: Nicole Ritz , Nigel Curtis

DOI: 10.1007/978-0-387-73960-1_13

关键词:

摘要: Avian (H5N1) influenza or “bird ‘flu” has received considerable attention in both the medical literature and mass media last few years. Despite tabloids’ portrayal of an imminent threat, to date there have been relatively cases humans spite large numbers infected poultry (Hien et al. 2004). However, this may be falsely reassuring. Most indications suggest that it is just a matter time until next pandemic occurs (Osterholm 2005). In words UK Chief Medical Officer: “most experts believe not question whether will another severe but when” (Department Health Although are agreed future almost inevitable, its timing unpredictable uncertain virus responsible H5N1 another, novel, strain A recent editorial described avian as “predicament extraordinary proportions” (Anonymous 2006). The dramatic impact on all levels health care including everyday work doctors. This chapter focuses clinical aspects about which paediatricians need familiar.

参考文章(50)
Avian Influenza A (H5N1) Infection in Humans The New England Journal of Medicine. ,vol. 353, pp. 1374- 1385 ,(2005) , 10.1056/NEJMRA052211
Scott A Harper, Keiji Fukuda, Timothy M Uyeki, Nancy J Cox, Carolyn B Bridges, None, Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report. ,vol. 55, pp. 1- 40 ,(2004)
Natalia A. Ilyushina, Nicolai V. Bovin, Robert G. Webster, Elena A. Govorkova, Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Research. ,vol. 70, pp. 121- 131 ,(2006) , 10.1016/J.ANTIVIRAL.2006.01.012
Robert G. Webster, Elena A. Govorkova, H5N1 Influenza — Continuing Evolution and Spread The New England Journal of Medicine. ,vol. 355, pp. 2174- 2177 ,(2006) , 10.1056/NEJMP068205
Barbara Freund, Stefan Gravenstein, Michael Elliott, Irene Miller, Zanamivir: a review of clinical safety. Drug Safety. ,vol. 21, pp. 267- 281 ,(1999) , 10.2165/00002018-199921040-00003
Anne Moscona, Oseltamivir Resistance — Disabling Our Influenza Defenses The New England Journal of Medicine. ,vol. 353, pp. 2633- 2636 ,(2005) , 10.1056/NEJMP058291
Shigeru Okamoto, Ichiro Kamiya, Kenji Kishida, Tetsuro Shimakawa, Tsuguya Fukui, Takeshi Morimoto, Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatric Infectious Disease Journal. ,vol. 24, pp. 575- 576 ,(2005) , 10.1097/01.INF.0000164799.33635.FE
Raphael Dolin, Influenza--interpandemic as well as pandemic disease. The New England Journal of Medicine. ,vol. 353, pp. 2535- 2537 ,(2005) , 10.1056/NEJMP058276
Jonathan A. McCullers, The Clinical Need for New Antiviral Drugs Directed against Influenza Virus The Journal of Infectious Diseases. ,vol. 193, pp. 751- 753 ,(2006) , 10.1086/500477
Jennifer L McKimm-Breschkin, Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion on Pharmacotherapy. ,vol. 3, pp. 103- 112 ,(2002) , 10.1517/14656566.3.2.103